<i id='19D46A792B'><strike id='19D46A792B'><tt id='19D46A792B'><pre id='19D46A792B'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
The cancer drug shortage isn’t new — and neither are the solutions 
J&J reports mixed data on next 
BioMarin wins approval for gene therapy to treat hemophilia A 
Bubonic plague hit France in 1720. Officials dithered. Sound familiar? 
Supreme Court strikes down use of affirmative action
J&J reports mixed data on next 
Biden outlines 'new path' to provide student loan relief after Supreme Court rejection 
Beyond aggravation: Constipation is an American epidemic 
Bright Health sells Medicare Advantage business to Molina 
Asahi Kasei to buy Calliditas, picking up kidney disease drug 
Walensky prepares to leave CDC — and Congress — behind 
Bird flu makes raw milk dangerous to consume, mouse study finds 
The high cost of giving birth even with insurance 
Some medical students still think black patients feel less pain 
Sports medicine is finally prioritizing gender equality 
